Test Price
2,800 AED✅ Home Collection Available
LRTOMT Gene Deafness, Autosomal Recessive Type 63 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Clinical Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Clinical Overview
The LRTOMT gene test detects autosomal recessive deafness type 63 (DFNB63), a profound prelingual sensorineural hearing loss caused by biallelic mutations in LRTOMT. This next‑generation sequencing (NGS) assay analyses the entire coding region with 99.9% sensitivity, enabling accurate carrier screening, early audiological intervention, and genetic counselling in affected Emirati families.
Comparative Accuracy
| Feature | Our Test (ISO 9001:2015 Lab) | Closest Alternative (Regional Lab) |
|---|---|---|
| Diagnostic Precision | Full LRTOMT gene sequencing (NGS) – 99.9% analytical sensitivity | Limited targeted mutation panel (~80% coverage of common variants) |
| Methodology | Illumina® NGS with Sanger confirmation | Genotyping arrays / MLPA – no full sequence data |
| Turnaround Time | 3–4 weeks | 5–6 weeks |
| DHA/MOHAP Approved | Yes (Facility License 1143) | Not always |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I emphasise that a positive LRTOMT result must be interpreted alongside pure‑tone audiometry and a three‑generation family pedigree. This test confirms the genetic aetiology, enabling timely cochlear implantation candidacy assessment when indicated; it does not predict the exact degree of functional hearing loss.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Test Interpretation
Critical Guidance: Do not discontinue any prescribed medication or audiological therapy without consulting your treating physician. Genetic test results are an adjunct to, not a replacement for, ongoing clinical care and hearing rehabilitation.
Exclusion Criteria & Red Flags
- Exclusion: Neonates requiring immediate hearing screening → refer to the universal newborn hearing screening programme; this genetic test is not a substitute for otoacoustic emissions (OAE) or auditory brainstem response (ABR).
- Red Flag: Sudden unilateral hearing loss with vertigo → proceed to emergency ENT evaluation for possible Meniere’s disease or acoustic neuroma, not elective genetic testing.
- Exclusion: Acute ear infection or recent ototoxic drug exposure – sample collection should be deferred until clinical resolution to avoid misleading epigenetic or haplotype interactions.
Patient FAQ & Clinical Guidance
1. What does a positive LRTOMT gene mutation result mean for my child?
A positive result confirms inherited non‑syndromic deafness type DFNB63, enabling early cochlear implant evaluation and informed genetic family planning. This test is a critical step in the diagnostic pathway for prelingual hearing loss.
2. Is the LRTOMT gene test covered by UAE health insurance?
Many UAE insurers cover medically necessary genetic tests when ordered by an ENT specialist or a geneticist. We offer direct billing verification via WhatsApp at +971 54 548 8731 to confirm your coverage before sample collection.
3. How should I prepare for the blood draw for this genetic test?
Fasting is not required for this test. A single blood sample (or a DNA FTA card) will be collected by our DHA‑licensed phlebotomist at your home, using our temperature-controlled cold-chain logistics. No special preparation is necessary.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed in strict compliance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure handling of all patient genomic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the integrity of our digital health records and tele-counselling services.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – governing clinical safety, patient consent, and professional accountability.
All clinical decisions must involve a DHA‑licensed physician. Our facility is ISO 9001:2015 certified and adheres to the highest international quality standards.
Clinical & Logistical Metadata
| Test Name | LRTOMT Gene Deafness, Autosomal Recessive Type 63 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) or DNA FTA card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | H90.5 (Sensorineural hearing loss, bilateral), H90.3 (Sensorineural hearing loss, unilateral) |
| LOINC Code | 81245-0 (Hereditary hearing loss gene panel sequencing) |
| DHA Facility License & Laboratory Address | License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians